$16.74
-0.25[-1.47%]
At close: Apr 23
$16.74
0[0.00%]
After Hours: 4:00PM EDT
ACADIA Pharmaceuticals
(NASDAQ:ACAD)ACADIA Pharmaceuticals Stock (NASDAQ:ACAD), Analyst Ratings, Price Targets, Predictions
ACADIA Pharmaceuticals Inc has a consensus price target of $27.71, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Needham, and JP Morgan on April 10, 2024, April 9, 2024, and March 25, 2024. With an average price target of $31.33 between Cantor Fitzgerald, Needham, and JP Morgan, there's an implied 87.18% upside for ACADIA Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Needham
JP Morgan
Morgan Stanley
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ACADIA Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 121.03% | Cantor Fitzgerald | Charles Duncan | → $37 | Reiterates | Overweight → Overweight | Get Alert |
| 04/09/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 91.16% | Needham | Ami Fadia | → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 49.34% | JP Morgan | Tessa Romero | $29 → $25 | Maintains | Overweight | Get Alert |
| 03/13/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 79.21% | Morgan Stanley | Jeffrey Hung | $40 → $30 | Maintains | Overweight | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 80.35% | Citigroup | David Hoang | $38 → $30.19 | Maintains | Buy | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 79.21% | RBC Capital | Gregory Renza | $35 → $30 | Maintains | Outperform | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 49.34% | Mizuho | Uy Ear | $39 → $25 | Downgrade | Buy → Neutral | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 132.97% | JMP Securities | Jason Butler | $44 → $39 | Maintains | Outperform | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 121.03% | Cantor Fitzgerald | Charles Duncan | $42 → $37 | Maintains | Overweight | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 85.19% | Baird | Joel Beatty | $40 → $31 | Maintains | Outperform | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 13.5% | Oppenheimer | Jay Olson | $25 → $19 | Maintains | Perform | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 79.21% | B of A Securities | Tazeen Ahmad | $33 → $30 | Maintains | Neutral | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 97.13% | Canaccord Genuity | Sumant Kulkarni | $40 → $33 | Maintains | Buy | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 97.13% | HC Wainwright & Co. | Andrew Fein | → $33 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 91.16% | Needham | Ami Fadia | $36 → $32 | Maintains | Buy | Get Alert |
| 03/01/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 73.24% | JP Morgan | Tessa Romero | $32 → $29 | Maintains | Overweight | Get Alert |
| 02/28/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 97.13% | HC Wainwright & Co. | Andrew Fein | → $33 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 150.9% | Cantor Fitzgerald | Charles Duncan | → $42 | Reiterates | Overweight → Overweight | Get Alert |
| 02/28/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.74 | 109.08% | RBC Capital | Gregory Renza | $36 → $35 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for ACADIA Pharmaceuticals (ACAD)?
The latest price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) was reported by Cantor Fitzgerald on April 10, 2024. The analyst firm set a price target for $37.00 expecting ACAD to rise to within 12 months (a possible 121.03% upside). 63 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ACADIA Pharmaceuticals (ACAD)?
The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ: ACAD) was provided by Cantor Fitzgerald, and ACADIA Pharmaceuticals reiterated their overweight rating.
When was the last upgrade for ACADIA Pharmaceuticals (ACAD)?
The last upgrade for ACADIA Pharmaceuticals Inc happened on January 24, 2024 when Needham raised their price target to $37. Needham previously had a hold for ACADIA Pharmaceuticals Inc.
When was the last downgrade for ACADIA Pharmaceuticals (ACAD)?
The last downgrade for ACADIA Pharmaceuticals Inc happened on March 12, 2024 when Mizuho changed their price target from $39 to $25 for ACADIA Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for ACADIA Pharmaceuticals (ACAD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating ACADIA Pharmaceuticals (ACAD) correct?
While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a reiterated with a price target of $0.00 to $37.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $16.74, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.